Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

Telehealth platform Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, experienced an 8% increase in its stock on Friday, May 30th, ...

Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

The direct-to-consumer telehealth company said the workforce reduction is unrelated to its weight-loss drug sector.

Investors are buying Hims & Hers Health ( HIMS 10.09%) stock hand over fist after the mail-order drugs company reported an earnings miss but a sales beat last night. But they're selling off shares of ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

As of 11:20 a.m. ET, Hims & Hers stock is surging to 11.2% and beyond, whereas both Eli Lilly and Novo Nordisk stocks are down 3.2%. Hims & Hers reported a surge in sales in the first quarter of ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

But they're selling off shares of Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the latter of which is a Hims & Hers partner now. As of 11:20 a.m. ET, Hims & Hers stock is surging to 11.2% ...